Non-small cell lung cancer with EGFR exon 21 L858R substitution mutation

Non-small cell lung cancer with an EGFR exon 21 L858R substitution mutation is an oncogene-driven subtype of epithelial lung malignancy, most frequently diagnosed as adenocarcinoma

It disproportionately impacts female patients, individuals who have never smoked or have a minimal smoking history, and populations of East Asian descent

It disproportionately impacts female patients, individuals who have never smoked or have a minimal smoking history, and populations of East Asian descent

Pathophysiologically, this disease is characterized by a specific missense mutation where arginine replaces leucine at codon 858 within the tyrosine kinase domain of the epidermal growth factor receptor, resulting in ligand-independent constitutive kinase activation and downstream signaling that accelerates cell proliferation and survival Clinically, identification of this biomarker defines an actionable tumor profile conferring sensitivity to targeted EGFR tyrosine kinase inhibitors

Pathophysiologically, this disease is characterized by a specific missense mutation where arginine replaces leucine at codon 858 within the tyrosine kinase domain of the epidermal growth factor receptor, resulting in ligand-independent constitutive kinase activation and downstream signaling that accelerates cell proliferation and survival

Clinically, identification of this biomarker defines an actionable tumor profile conferring sensitivity to targeted EGFR tyrosine kinase inhibitors